

# HOUSE BILL 1430

J1

3lr1665

---

By: **Delegate Nathan–Pulliam**

Introduced and read first time: February 18, 2013

Assigned to: Rules and Executive Nominations

---

## A BILL ENTITLED

1 AN ACT concerning

2 **Task Force on Pharmacogenomics**

3 FOR the purpose of establishing a Task Force on Pharmacogenomics; providing for the  
4 membership, chair, staffing, and duties of the Task Force; providing that a  
5 member of the Task Force may not receive certain compensation but is entitled  
6 to a certain reimbursement; requiring the Task Force to provide a certain report  
7 to the Governor and to certain committees of the General Assembly on or before  
8 a certain date; providing for the termination of this Act; and generally relating  
9 to a Task Force on Pharmacogenomics.

10 SECTION 1. BE IT ENACTED BY THE GENERAL ASSEMBLY OF  
11 MARYLAND, That:

12 (a) There is a Task Force on Pharmacogenomics.

13 (b) The Task Force consists of the following members, appointed by the  
14 Governor:

15 (1) one representative of a School of Public Health in the State;

16 (2) one representative of a School of Nursing in the State;

17 (3) one representative of a School of Pharmacy in the State;

18 (4) one representative of an academic center on health disparities;

19 (5) one representative of an academic human genomic center;

20 (6) one representative of a community–based nonprofit health  
21 disparities advocacy organization;

---

EXPLANATION: CAPITALS INDICATE MATTER ADDED TO EXISTING LAW.

[Brackets] indicate matter deleted from existing law.



- 1 (7) one representative of a mental health advocacy organization;
- 2 (8) one representative of an addictions advocacy organization;
- 3 (9) one representative of a pain and chronic disease advocacy  
4 organization;
- 5 (10) one representative of the Maryland Hospital Association;
- 6 (11) two representatives of health care accreditation organizations;
- 7 (12) one representative of the Maryland Health Benefit Exchange;
- 8 (13) one representative of an employer health trade association;
- 9 (14) one representative of a laboratory vendor; and
- 10 (15) one representative of a commercial testing provider.

11 (c) The Governor shall designate the chair of the Task Force.

12 (d) The Department of Health and Mental Hygiene shall provide staff for the  
13 Task Force.

14 (e) A member of the Task Force:

- 15 (1) may not receive compensation as a member of the Task Force; but
- 16 (2) is entitled to reimbursement for expenses under the Standard  
17 State Travel Regulations, as provided in the State budget.

18 (f) The Task Force shall:

- 19 (1) examine the availability of genomic testing and its application to  
20 clinical practice in the State;
- 21 (2) examine how the State can adopt genomic testing as the standard  
22 of care for State residents;
- 23 (3) determine the possible pharmacoeconomic implications of adopting  
24 genomic testing across the State; and
- 25 (4) determine how health disparities may be reduced when genomic  
26 testing is added to the State armamentarium.

27 (g) On or before June 30, 2014, the Task Force shall report its findings and  
28 recommendations to the Governor and, in accordance with § 2-1246 of the State

1 Government Article, the Senate Finance Committee and the House Health and  
2 Government Operations Committee.

3 SECTION 2. AND BE IT FURTHER ENACTED, That this Act shall take effect  
4 July 1, 2013. It shall remain effective for the period of 1 year and 2 months and, at the  
5 end of August 30, 2014, with no further action required by the General Assembly, this  
6 Act shall be abrogated and of no further force and effect.